FY2025 Earnings Forecast for HALO Issued By Zacks Research

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Zacks Research upped their FY2025 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a report issued on Tuesday, December 10th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of $4.45 per share for the year, up from their prior estimate of $4.40. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $3.80 per share. Zacks Research also issued estimates for Halozyme Therapeutics' Q3 2026 earnings at $1.44 EPS and FY2026 earnings at $5.84 EPS.

Several other equities research analysts have also commented on HALO. Piper Sandler upped their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a "neutral" rating in a research report on Monday, November 4th. Wells Fargo & Company downgraded Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lifted their price objective for the stock from $58.00 to $62.00 in a report on Monday, October 7th. Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. HC Wainwright reissued a "buy" rating and issued a $68.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, November 20th. Finally, JMP Securities boosted their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $61.11.

Halozyme Therapeutics Trading Down 0.1 %

Shares of NASDAQ HALO traded down $0.03 during trading on Friday, reaching $47.80. The company had a trading volume of 539,615 shares, compared to its average volume of 1,356,437. The company's fifty day moving average price is $51.65 and its 200-day moving average price is $53.89. Halozyme Therapeutics has a 12 month low of $33.15 and a 12 month high of $65.53. The stock has a market cap of $6.08 billion, a P/E ratio of 15.84, a PEG ratio of 0.43 and a beta of 1.23. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HALO. International Assets Investment Management LLC acquired a new position in Halozyme Therapeutics during the second quarter valued at $33,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Halozyme Therapeutics in the second quarter worth about $49,000. GAMMA Investing LLC raised its position in shares of Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company's stock worth $50,000 after acquiring an additional 350 shares during the period. Toth Financial Advisory Corp acquired a new position in shares of Halozyme Therapeutics in the third quarter worth about $57,000. Finally, FSC Wealth Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the third quarter worth about $65,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total transaction of $532,600.00. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at $9,254,244.56. The trade was a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 40,000 shares of company stock valued at $2,242,100. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.